Edition:
India

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

83.89USD
2:29am IST
Change (% chg)

$-1.79 (-2.09%)
Prev Close
$85.68
Open
$85.96
Day's High
$86.70
Day's Low
$83.56
Volume
181,784
Avg. Vol
213,932
52-wk High
$99.80
52-wk Low
$44.58

Select another date:

Wed, Nov 15 2017

BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Sage Therapeutics announces proposed public offering of common stock

* Sage Therapeutics announces proposed public offering of common stock

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

UPDATE 1-Sage Therapeutics postpartum depression drug meets goal in two trials

Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies, sending shares of the company up about 17 percent in pre-market trade.

REFILE-Sage Therapeutics postpartum depression drug meets main goal

Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints

* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression

BRIEF-Sage Therapeutics announces qtrly loss per share $1.97‍​

* Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update

Sage's seizure drug fails key trial, shares slump

Sage Therapeutics Inc's shares tumbled 23 percent on Tuesday after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.

BRIEF-Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone

* Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone in super-refractory status epilepticus

Sage's seizure disorder drug fails late-stage trial

Sept 12 Sage Therapeutics Inc said on Tuesday its drug to treat a life-threatening seizure disorder failed to meet the main goal of a late-stage trial.

Select another date: